Myeloperoxidase modulation by LDL apheresis in familial hypercholesterolemia

Area of Science:

• Cardiovascular Science
• Biochemistry
• Inflammation Research

Background:

• Myeloperoxidase (MPO) is a key indicator of vulnerable atherosclerotic plaques and links inflammation to cardiovascular disease (CVD).
• Hypercholesterolemia is a known risk factor for atherosclerosis and systemic inflammation.

Purpose of the Study:

• To investigate elevated MPO serum levels in Familial Hypercholesterolemia (FH).
• To determine if acute reduction of total cholesterol (TC) impacts MPO concentration in FH patients.

Main Methods:

• Utilized LDL-apheresis (LDL-A) in FH patients to create a model of rapid TC fluctuation.
• Measured serum MPO levels via ELISA and MPO in peripheral leukocytes via immunofluorescence.
• Monitored MPO levels serially before and up to 14 days after LDL-A treatment.

Main Results:

• MPO concentrations in serum and leukocytes were significantly higher in FH patients compared to controls.
• MPO levels decreased in parallel with TC reduction during LDL-A treatment.
• Plasma TC was identified as the sole significant predictor influencing serum MPO levels (p < 0.0001).

Conclusions:

• Serum MPO levels in FH patients are directly modulated by TC concentrations, as demonstrated by LDL-A treatment.
• Further research is warranted to explore the therapeutic potential of LDL-A-induced MPO reduction in managing CVD risk.